Embecta (EMBC) to Post Quarterly Earnings on Friday

Embecta (NASDAQ:EMBC) is projected to issue its Q3 2026 results before the market opens on Friday, August 7th. Analysts expect Embecta to announce earnings of $0.26 per share and revenue of $254.5260 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.

Embecta (NASDAQ:EMBC) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. During the same period in the previous year, the firm earned $0.70 EPS. Embecta’s revenue for the quarter was down 14.4% on a year-over-year basis. On average, analysts expect Embecta to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Embecta Stock Performance

Shares of EMBC stock opened at $3.82 on Wednesday. Embecta has a 1 year low of $2.77 and a 1 year high of $15.55. The stock has a market cap of $226.64 million, a PE ratio of 2.01 and a beta of 0.81. The business’s fifty day moving average is $3.31 and its 200-day moving average is $6.80.

Analyst Upgrades and Downgrades

EMBC has been the subject of several research reports. Bank of America decreased their target price on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research note on Monday, May 18th. Weiss Ratings cut shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. Mizuho cut their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, BTIG Research cut shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Three investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Embecta presently has a consensus rating of “Reduce” and an average price target of $11.00.

Institutional Investors Weigh In On Embecta

Large investors have recently made changes to their positions in the company. Brooklyn Investment Group lifted its position in shares of Embecta by 5.9% during the 4th quarter. Brooklyn Investment Group now owns 19,736 shares of the company’s stock worth $234,000 after purchasing an additional 1,098 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Embecta by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock valued at $209,000 after purchasing an additional 1,110 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Embecta by 2.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after purchasing an additional 1,159 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Embecta by 1.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,271 shares of the company’s stock worth $1,785,000 after buying an additional 1,520 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after buying an additional 1,574 shares in the last quarter. Institutional investors own 93.83% of the company’s stock.

Embecta News Roundup

Here are the key news stories impacting Embecta this week:

• Neutral Sentiment: Multiple law firms announced or promoted a class action covering investors who purchased Embecta securities between November 25, 2025, and May 4, 2026. The lead-plaintiff deadline is August 17, 2026. The litigation remains at an early stage, and the allegations have not been proven. Pomerantz investor alert
• Negative Sentiment: The lawsuits allege that Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. Several notices cite a major revenue shortfall, a roughly 57% single-day stock collapse, and a substantial reduction in earnings guidance as the events that allegedly revealed the problems. Bleichmar Fonti & Auld class action notice
• Negative Sentiment: The legal developments add potential costs, management distraction, and uncertainty regarding possible damages or settlements. They also keep attention focused on Embecta’s weak fundamentals: the latest reported quarter missed revenue and EPS estimates, with revenue down 14.4% year over year. Portnoy Law Firm class action announcement

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.